# Swiss studY for the Treatment of COPD Patients With the Free combiNation of indacatERol and GlYcopyrroniumbromide.

> **NCT01699685** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 79 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease: COPD

## Interventions

- **DRUG:** QAB149
- **DRUG:** Placebo
- **DRUG:** NVA237

## Key facts

- **NCT ID:** NCT01699685
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2016-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01699685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01699685, "Swiss studY for the Treatment of COPD Patients With the Free combiNation of indacatERol and GlYcopyrroniumbromide.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01699685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*